SCHEMBL6311433

SCHEMBL6311433

CC(=O)c1ccc(Sc2ccc(C(=O)NC3CC4CCN(CC4)C3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 7/20 0.57
HPGD P15428 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
EZH2 Q15910 1/20 0.44
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
MMP2 P08253 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6306336 0.94 CHRNA7 (0.66) CHRNA7HPGDLMNAL3MBTL1EZH2
SCHEMBL6306329 0.94 CHRNA7 (0.66) CHRNA7HPGDLMNAL3MBTL1EZH2
SCHEMBL6305755 0.90 CHRNA7 (0.53) CHRNA7HPGDEZH2ALDH1A1PKM
SCHEMBL6305169 0.89 CHRNA7 (0.68) CHRNA7EZH2HTR3EHTR3BALOX15
SCHEMBL6303147 0.89 CHRNA7 (0.58) CHRNA7EZH2HTR3EHTR3BALOX15
SCHEMBL6311124 0.89 CHRNA7 (0.53) CHRNA7L3MBTL1EZH2HTR3EHTR3B
SCHEMBL6310327 0.88 CHRNA7 (0.75) CHRNA7EZH2HTR3EHTR3BALOX15
SCHEMBL6303143 0.88 CHRNA7 (0.60) CHRNA7EZH2HTR3EHTR3BALOX15
SCHEMBL6303351 0.88 CHRNA7 (0.57) CHRNA7EZH2HTR3EHTR3BALOX15
SCHEMBL6306964 0.87 CHRNA7 (0.54) CHRNA7L3MBTL1ALDH1A1PKMMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US claimed
EP-1480977-A2 SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-12-01 EP claimed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
WO-2003070728-A2 AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO claimed
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US disclosed
EP-1480977-A2 SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-12-01 EP disclosed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003070728-A2 AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236279-A1 Substituted-aryl compounds for treatment of disease NAT1, CYP7A1, CYP7B1 CHRNA7 2937/4885HPGD 794/4885LMNA 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.